The combination of ERα antagonism and ERβ agonism may be especially relevant for the chemoprevention of breast cancer as ER antagonism serves as the basis of current chemo-preventative agents [29,31,32,73,74], while ERβ specific agonists have recently been identified as having potential for the chemoprevention of breast cancer [19,22]. The gene discussed is ESR2; the disease is breast cancer.